Although all patients had HR+/HER2− advanced breast cancer and were receiving an initial ET-based regimen for advanced disease, the mean duration of this treatment was only 6.7 months, and this short follow-up time must be considered when interpreting the results. Here, HR is linked to breast carcinoma.